Infectious and inflammatory myelopathies

CONTINUUM Lifelong Learning in Neurology

Volumn 14, Issue 3, 2008, Pages 36-57

  Wingerchuk, Dean M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 76749151051     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000324123.16947.3c     Document Type: Article

References (43)

1. Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. Nat Rev Neurosci 2003;4(12):991-1001.
2. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346(3):158-164.
3. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270-1272.
4. Dal Pan GJ, Glass JD, McArthur JC. Clinicopathological correlations of HIV-1-associated vacuolar myelopathy: an autopsy-based case-control study. Neurology 1994;44(11):2159-2164.
5. de Seze J, Lanctin C, Lebrun C, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005;65(12):1950-1953.
6. Di Rocco A, Bottiglieri T, Werner P, et al. Abnormal cobalamin-dependent transmethylation in AIDS-associated myelopathy. Neurology 2002;58(5):730-735.
7. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354(9):942-955.
8. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotrophic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2(8452):407-410.
9. Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007;68(19):1614-1617.
10. Hollander H, Schaefer PW, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 22-2005. An 81-year-old man with cough, fever, and altered mental status. N Engl J Med 2005;353(3):287-295.
11. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58(1):143-146.
12. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2(2):117-127.
13. Krishnan C, Kaplan AI, Pardo CA, et al. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep 2006;6(3):236-243.
14. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-477.
15. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106-2112.
16. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125(pt 7):1450-1461.
17. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998,51(4):1219-1220.
18. Marra CM. Neurosyphilis. Curr Neurol Neurosci Rep 2004;4(6):435-440.
19. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005;4(9):543-555.
20. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65(9):1479-1482.
21. Nash D, Mostashair F, Fine A, et al. The outbreak of West Nile virus infection the New York City area in 1999. N Engl J Med 2001;344(24):1807-1814.
22. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-952.
23. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1(8488):1031-1032. (Pubitemid 16102987)
24. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13(2):256-259.
25. Petito CK, Navia BA, Cho ES, et al. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985;312(14):874-879.
26. Petito CK, Vecchio D, Chen YT. HIV antigen and DNA in AIDS spinal cords correlate with macrophage infiltration but not with vacuolar myelopathy. J Neuropathol Exp Neurol 1994;53(1):86-94.
27. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006a;63(3):390-396.
28. Pittock SJ, Lennon VA, Wingerchuk DM, et al. The prevalence of non-organ-specific autoantibodies and NMO-IgG in neuromyelitis optica (NMO) and related disorders. Neurology 2006b;66(suppl):A307.
29. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006c;63(7):964-968.
30. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130(pt 5):1194-1205.
31. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004;63(6):1081-1083.
32. Sampathkumar P. West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin Proc 2003;78(9):1137-1143.
33. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59(4):499-505.
34. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007;252(1):57-61.
35. Wareham DW, Breuer J. Herpes zoster. BMJ 2007;334(7605):1211-1215.
36. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13(1):128-132. (Pubitemid 46152772)
37. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating diseases. Ann Neurol 1999;46(6):878-886.
38. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse following longitudinally extensive transverse myelitis. Ann Neurol 2006;59(3): 566-569.
39. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63(7):957-963.
40. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6(9):810-815.
41. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66(10):1485-1489.
42. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2007;20(3):343-350.
43. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2005;7(3):173-182.